Ed Arce
Stock Analyst at WestPark Capital
(4.23)
# 447
Out of 5,090 analysts
431
Total ratings
46.27%
Success rate
17.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.15 | +97.88% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $35.00 | -14.29% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $8.18 | +46.70% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.32 | +1,086.71% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $7.12 | +742.70% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.57 | +379.23% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.11 | +216.30% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $6.10 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $1.27 | +374.31% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $9.95 | +603.52% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $35.01 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $3.32 | +7,128.92% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.30 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $6.15 | +420.33% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $220.70 | -84.14% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $54.50 | +37.61% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $69.38 | +3.78% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $579.99 | -30.17% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $5.81 | -5.25% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $37.00 | +156.76% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.33 | +15.50% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $35.17 | +36.48% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $29.43 | -74.52% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.50 | +892.85% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $15.20 | -14.47% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.12 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $45.45 | -44.99% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.34 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $38.58 | -81.86% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $47.25 | -55.56% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.14 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.15
Upside: +97.88%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $35.00
Upside: -14.29%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $8.18
Upside: +46.70%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.32
Upside: +1,086.71%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $7.12
Upside: +742.70%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.57
Upside: +379.23%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.11
Upside: +216.30%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.10
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $1.27
Upside: +374.31%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $9.95
Upside: +603.52%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $35.01
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $3.32
Upside: +7,128.92%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $6.15
Upside: +420.33%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $220.70
Upside: -84.14%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $54.50
Upside: +37.61%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $69.38
Upside: +3.78%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $579.99
Upside: -30.17%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $5.81
Upside: -5.25%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $37.00
Upside: +156.76%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.33
Upside: +15.50%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $35.17
Upside: +36.48%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $29.43
Upside: -74.52%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.50
Upside: +892.85%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $15.20
Upside: -14.47%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $45.45
Upside: -44.99%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.34
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $38.58
Upside: -81.86%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $47.25
Upside: -55.56%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.14
Upside: -